Leerink Partnrs Issues Negative Estimate for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Stock analysts at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($0.52) per share for the quarter, down from their previous forecast of ($0.51). The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($3.40) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals' Q4 2025 earnings at ($0.48) EPS and FY2025 earnings at ($2.06) EPS.

Other research analysts also recently issued research reports about the company. Citigroup lowered their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Wednesday, November 27th. Sanford C. Bernstein lowered their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a report on Friday, November 29th. Piper Sandler decreased their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. Chardan Capital reiterated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $43.33.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR traded down $0.77 during trading hours on Friday, hitting $20.76. 23,744,831 shares of the company were exchanged, compared to its average volume of 3,128,722. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. Arrowhead Pharmaceuticals has a fifty-two week low of $17.05 and a fifty-two week high of $36.72. The company has a market cap of $2.58 billion, a price-to-earnings ratio of -4.14 and a beta of 0.97. The firm's fifty day moving average is $20.73 and its 200 day moving average is $22.04.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ARWR. World Investment Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 3.8% during the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company's stock valued at $371,000 after acquiring an additional 700 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company's stock worth $88,000 after buying an additional 788 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Arrowhead Pharmaceuticals by 1.5% in the 3rd quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company's stock valued at $1,199,000 after acquiring an additional 886 shares during the last quarter. State of Alaska Department of Revenue boosted its position in Arrowhead Pharmaceuticals by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 14,417 shares of the biotechnology company's stock worth $279,000 after purchasing an additional 980 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Arrowhead Pharmaceuticals by 5.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,262 shares of the biotechnology company's stock valued at $586,000 after purchasing an additional 1,523 shares in the last quarter. Institutional investors own 62.61% of the company's stock.

Insider Activity

In other news, Director Adeoye Y. Olukotun sold 2,850 shares of the business's stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. Following the transaction, the director now directly owns 36,740 shares of the company's stock, valued at approximately $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William D. Waddill sold 3,748 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $21.90, for a total transaction of $82,081.20. Following the sale, the director now directly owns 44,125 shares in the company, valued at $966,337.50. The trade was a 7.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 146,473 shares of company stock worth $2,937,847 over the last ninety days. Company insiders own 4.50% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.